Alluvi, formerly BI 4744, presents a notable advance in weight management treatment. This dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide targets demonstrates impressive results in https://alluvi-research.co.uk/product/alluvi-retatrutide-40mg-rd-only/